Clinical Trial

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

Name: A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) — clinical trial record (NCT07011043)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.

Protocol Amendment History 7 amendments

This ClinicalTrials.gov record has been amended 7 times since 2025-06-06; most recent amendment 2026-03-24.

Trial Details

NCT Number	NCT07011043
Lead Sponsor	Climb Bio, Inc.
Conditions	Systemic Lupus Erythematosus
Enrollment	30 participants
Start Date	2025-07-10
Primary Completion	2027-04 (estimated)
Study Completion	2027-04 (estimated)
Updated on ClinicalTrials.gov	2026-03-27